AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
CTLA-4 antibody blockade increases tumor immunity in cancer patients.
2003 JUN 18 - (NewsRx.com & NewsRx.net) -- A CTLA-4 antibody blockade increased tumor immunity in some previously vaccinated cancer patients.
"A large number of cancer-associated gene products evoke immune recognition, but host reactions rarely impede disease progression. The weak immunogenicity of nascent tumors contributes to this failure in host defense. Therapeutic vaccines that enhance dendritic cell presentation of cancer antigens increase specific cellular and humoral responses, thereby effectuating tumor destruction in some cases," scientists in the United States report.
"The attenuation of T cell activation by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) further limits the potency of tumor immunity," said F. Stephen Hodi and colleagues at Harvard Medical School and the University of California-Berkeley. "In murine systems, the administration of antibodies that block CTLA-4 function inhibits the growth of moderately immunogenic tumors and, in combination with cancer vaccines, increases the rejection of poorly immunogenic tumors, albeit with a loss of tolerance to normal differentiation antigens. To gain a preliminary assessment of the biologic activity of antagonizing CTLA-4 function in humans, we infused a CTLA-4 blocking antibody (MDX-CTLA4) into nine previously immunized advanced cancer patients."
The investigators found, "MDX-CTLA4 stimulated extensive tumor necrosis with lymphocyte and granulocyte infiltrates in three of three metastatic melanoma patients and the reduction or stabilization of CA-125 levels in two of two metastatic ovarian carcinoma ...
- Cancer vaccine delivers antigen to dendritic cells.
- Newspaper article from: Cancer Vaccine Week February 9, 2004 700+ words
...Proceedings of the National Academy of Sciences...adenoviral vector cancer vaccine that delivers...Proceedings of the National Academy of Sciences...contacted at: National Academy of Sciences...subject areas of Cancer Vaccine, Immunology...
- New Yorkers Come Together to Discover New Ways to Fight Cancer; - Local...
- Press release article from: PR Newswire September 30, 2002 700+ words
...the launch of the Cancer Vaccine Collaborative, a...Initiating the Cancer Vaccine Collaborative in...Tormey. "As the Cancer Vaccine Collaborative matures...26 members of the National Academy of Sciences, and...
- Medarex and Cell Genesys Initiate Phase I Clinical Trial of MDX-010 in...
- Press release article from: PR Newswire September 13, 2004 700+ words
...GVAX(R) prostate cancer vaccine, administered in...Proceedings of the National Academy of Sciences, as...GVAX(R) prostate cancer vaccine as a single agent...this combination of cancer vaccine and antibody therapy...
- Genzyme Molecular Oncology Announces Initiation of Kidney Cancer and Melanoma...
- Press release article from: PR Newswire October 3, 2000 700+ words
...melanoma gene therapy cancer vaccine trials currently...phase 1-2 breast cancer vaccine trial utilizing dendritic...Proceedings of the National Academy of Sciences (volume...clinical study of a cancer vaccine to treat metastatic...
- Somatix's Collaboration Presents Interim Phase I/II Data For Its GVAX Cancer...
- Press release article from: Business Wire May 6, 1996 700+ words
...trial of its GVAX cancer vaccine for advanced melanoma...interval. The GVAX cancer vaccine is the company...Proceedings of the National Academy of Sciences detailed...product, the GVAX cancer vaccine, is being tested...
- Cell Genesys to Expand Clinical Trials for GVAX(TM) Cancer Vaccine For Prostate...
- Press release article from: PR Newswire November 20, 1998 700+ words
...cancer can be targeted with this novel cancer vaccine strategy." GVAX vaccine for prostate...I/II clinical trials of the GVAX cancer vaccine in lung cancer and melanoma. These...October issue of the Proceedings of the National Academy of Sciences by a team of investigators...
- Telomerase Used as Cancer Vaccine.(Brief Article)
- Newspaper article from: Applied Genetics News April 1, 2000 700+ words
...Center are investigating the use of telomerase as a universal cancer vaccine. Telomerase, an enzyme that maintains normal chromosome...reported in the April 4 issue of the Proceedings of the National Academy of Science. Zanetti theorized that by immunizing lymphocytes...
- Antibody Therapy Can Increase Effectiveness of Cancer Vaccine, Preliminary...
- News wire article from: Ascribe Higher Education News Service April 1, 2003 700+ words
...on April 1 in the Early Edition of the Proceedings of the National Academy of Sciences (www.pnas.org), tested the effect of...animal experiments, Allison's team showed that combining a cancer vaccine with an antibody able to block CTLA-4 resulted in an especially...
- Moores UC San Diego Cancer Center Launches Human Trial for Prostate Cancer...
- News wire article from: Europe Intelligence Wire June 25, 2003 700+ words
...international headlines when published in the Proceedings of the National Academy of Sciences, a major scientific journal, in April 2000...brings us closer to the possibility of developing a universal cancer vaccine, which puts this work in a different category than anything...
- The Immune Response Corporation Initiates Collaboration with the University of...
- Press release article from: PR Newswire December 10, 1996 700+ words
...to enroll up to 12 individuals. The experimental brain cancer vaccine to be evaluated in this clinical trial consists of irradiated...data from preclinical studies in the "Proceedings of the National Academy of Sciences." Essentially, the results showed the vaccine...
Source: HighBeam Research, CTLA-4 antibody blockade increases tumor immunity in cancer patients.